Pain Management Drugs Market Share, Trends & Forecast, 2032 

Pain Management Drugs Market Size - By Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine), Indication (Arthritic, Neuropathic, Cancer), Pain Type (Chronic, Acute), Distribution Channel (Hospital, Retail, Online), Global Forecast (2023 – 2032)

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast calculation

1.4&nbsp;&nbsp;&nbsp; Covid-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data sources

1.6.1&nbsp;&nbsp;&nbsp; Secondary

1.6.1.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.1.2&nbsp;&nbsp;&nbsp;Public sources

1.6.2&nbsp;&nbsp;&nbsp; Primary

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Pain management drugs market 360&ordm; synopsis, 2018 &ndash; 2032 (USD Million)

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Region trends

2.1.3&nbsp;&nbsp;&nbsp; Drug class trends

2.1.4&nbsp;&nbsp;&nbsp; Indication trends

2.1.5&nbsp;&nbsp;&nbsp; Pain type trends

2.1.6&nbsp;&nbsp;&nbsp; Distribution channel trends

Chapter 3&nbsp;&nbsp;&nbsp;Pain Management Drugs Market Insights

3.1&nbsp;&nbsp;&nbsp; Industry landscape, 2018 &ndash; 2032 (USD Million)

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Rise in incidences of chronic pain

3.2.1.2&nbsp;&nbsp;&nbsp;Increasing number of surgical procedures

3.2.1.3&nbsp;&nbsp;&nbsp;Increasing demand for non-opioid analgesics

3.2.1.4&nbsp;&nbsp;&nbsp;Increase in geriatric population

3.2.1.5&nbsp;&nbsp;&nbsp;Favorable regulatory scenario

3.2.1.6&nbsp;&nbsp;&nbsp;Technological advancements in drug delivery

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;Side effects and safety concerns

3.2.2.2&nbsp;&nbsp;&nbsp;Patent expirations and generic competition

3.2.2.3&nbsp;&nbsp;&nbsp;Availability of alternative therapies and non-pharmacological approaches

3.2.2.4&nbsp;&nbsp;&nbsp;High development costs and lengthy approval processes

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By drug class

3.3.2&nbsp;&nbsp;&nbsp; By indication

3.3.3&nbsp;&nbsp;&nbsp; By pain type

3.3.4&nbsp;&nbsp;&nbsp; By distribution channel

3.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Global company market share analysis, 2022

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix, 2022

4.5&nbsp;&nbsp;&nbsp; Strategic dashboard, 2022

Chapter 5&nbsp;&nbsp;&nbsp;Pain Management Drugs Market Estimates and Forecast, By Drug Class (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by drug class

5.2&nbsp;&nbsp;&nbsp; NSAIDS

5.3&nbsp;&nbsp;&nbsp; Anesthetics

5.4&nbsp;&nbsp;&nbsp; Anticonvulsants

5.5&nbsp;&nbsp;&nbsp; Antimigraine drugs

5.6&nbsp;&nbsp;&nbsp; Antidepressant drugs

5.7&nbsp;&nbsp;&nbsp; Opioids

5.8&nbsp;&nbsp;&nbsp; Non-narcotic analgesics

5.9&nbsp;&nbsp;&nbsp; Other drugs

Chapter 6&nbsp;&nbsp;&nbsp;Pain Management Drugs Market Estimates and Forecast, By Indication (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by indication

6.2&nbsp;&nbsp;&nbsp; Arthritic pain

6.3&nbsp;&nbsp;&nbsp; Neuropathic pain

6.4&nbsp;&nbsp;&nbsp; Cancer pain

6.5&nbsp;&nbsp;&nbsp; Chronic back pain

6.6&nbsp;&nbsp;&nbsp; Post-operative pain

6.7&nbsp;&nbsp;&nbsp; Migraine

6.8&nbsp;&nbsp;&nbsp; Fibromyalgia

6.9&nbsp;&nbsp;&nbsp; Bone fracture

6.10&nbsp;&nbsp;&nbsp; Muscle sprain/strain

6.11&nbsp;&nbsp;&nbsp; Acute appendicitis

6.12&nbsp;&nbsp;&nbsp; Other indications

Chapter 7&nbsp;&nbsp;&nbsp;Pain Management Drugs Market Estimates and Forecast, By Pain Type (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by pain type

7.2&nbsp;&nbsp;&nbsp; Chronic pain

7.3&nbsp;&nbsp;&nbsp; Acute pain

Chapter 8&nbsp;&nbsp;&nbsp;Pain Management Drugs Market Estimates and Forecast, By Distribution Type (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by distribution channel

8.2&nbsp;&nbsp;&nbsp; Hospital pharmacies

8.3&nbsp;&nbsp;&nbsp; Retail pharmacies

8.4&nbsp;&nbsp;&nbsp; Online pharmacies

Chapter 9&nbsp;&nbsp;&nbsp;Pain Management Drugs Market Estimates and Forecast, By Region (USD Million)

9.1&nbsp;&nbsp;&nbsp; North America

9.1.1&nbsp;&nbsp;&nbsp; U.S.

9.1.2&nbsp;&nbsp;&nbsp; Canada

9.2&nbsp;&nbsp;&nbsp; Europe

9.2.1&nbsp;&nbsp;&nbsp; Germany

9.2.2&nbsp;&nbsp;&nbsp; UK

9.2.3&nbsp;&nbsp;&nbsp; France

9.2.4&nbsp;&nbsp;&nbsp; Spain

9.2.5&nbsp;&nbsp;&nbsp; Italy

9.2.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.3&nbsp;&nbsp;&nbsp; Asia Pacific

9.3.1&nbsp;&nbsp;&nbsp; China

9.3.2&nbsp;&nbsp;&nbsp; Japan

9.3.3&nbsp;&nbsp;&nbsp; India

9.3.4&nbsp;&nbsp;&nbsp; Australia

9.3.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.4&nbsp;&nbsp;&nbsp; Latin America

9.4.1&nbsp;&nbsp;&nbsp; Brazil

9.4.2&nbsp;&nbsp;&nbsp; Mexico

9.4.3&nbsp;&nbsp;&nbsp; Rest of Latin America

9.5&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

9.5.1&nbsp;&nbsp;&nbsp; South Africa

9.5.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.5.3&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; ENDO HEALTH SOLUTIONS, INC.

10.2&nbsp;&nbsp;&nbsp; Merck &amp; Co., Inc.

10.3&nbsp;&nbsp;&nbsp; Novartis AG

10.4&nbsp;&nbsp;&nbsp; Pfizer, Inc.

10.5&nbsp;&nbsp;&nbsp; Sanofi S.A.

10.6&nbsp;&nbsp;&nbsp; Mylan N.V.

10.7&nbsp;&nbsp;&nbsp; Teva Pharmaceutical Industries Ltd.

10.8&nbsp;&nbsp;&nbsp; Ely Lilly and Company

10.9&nbsp;&nbsp;&nbsp; Abbott Laboratories

10.10&nbsp;&nbsp;&nbsp; Purdue Pharma L.P.

10.11&nbsp;&nbsp;&nbsp; GlaxoSmithKline Plc

10.12&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson

10.13&nbsp;&nbsp;&nbsp; F. Hoffmann La Roche Ltd. 
&nbsp;

Pain Management Drugs Market

Get a free sample of this report